Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 20/20 | 0.74 |
| ▸ | HTR2B | P41595 | 20/20 | 0.74 |
| ▸ | HTR2A | P28223 | 19/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19878804 | 0.85 | HTR2C (1.00) | HTR2CHTR2BHTR2A | |
| SCHEMBL29528033 | 0.85 | HTR2C (1.00) | HTR2CHTR2BHTR2A | |
| SCHEMBL19878802 | 0.85 | HTR2C (1.00) | HTR2CHTR2BHTR2A | |
| SCHEMBL31022397 | 0.82 | HTR2C (0.66) | HTR2CHTR2BHTR2A | |
| SCHEMBL26915044 | 0.82 | HTR2C (0.66) | HTR2CHTR2BHTR2A | |
| SCHEMBL31245414 | 0.80 | HTR2C (0.56) | HTR2CHTR2BHTR2A | |
| SCHEMBL30565563 | 0.79 | HTR2C (0.62) | HTR2CHTR2BHTR2A | |
| SCHEMBL2016835 | 0.78 | HTR2C (0.54) | HTR2CHTR2BHTR2A | |
| SCHEMBL692033 | 0.77 | HTR2A (0.67) | HTR2CHTR2BHTR2A | |
| SCHEMBL31022150 | 0.75 | HTR2A (0.58) | HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022007866-A1 | FUSED TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | 深圳信立泰药业股份有限公司 | 2022-01-13 | — | — | WO | disclosed |
| EP-1641796-B1 | 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | HOFFMANN LA ROCHE (CH) | 2007-06-06 | — | — | EP | disclosed |
| US-7208494-B2 | 5HT2c receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7098337-B2 | 1,2,3,4,9,9a-hexahydro-2,4a,5-triaza-fluorene and 1,2,3,4-tetrahydro-2,4a,5-triaza-fluorene derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-08-29 | — | — | US | disclosed |
| US-7098337-B2 | 1,2,3,4,9,9a-hexahydro-2,4a,5-triaza-fluorene and 1,2,3,4-tetrahydro-2,4a,5-triaza-fluorene derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-08-29 | — | — | US | disclosed |
| EP-1641796-A1 | 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-05 | — | — | EP | disclosed |
| EP-1472255-B1 | AZA-ARYLPIPERAZINES | HOFFMANN LA ROCHE (CH) | 2006-03-01 | — | — | EP | disclosed |
| US-20050026925-A1 | 5HT2c receptor agonists | HOFFMANN-LA ROCHE INC. | 2005-02-03 | — | — | US | disclosed |
| WO-2005000849-A1 | 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | disclosed |
| EP-1472255-A1 | AZA-ARYLPIPERAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-03 | — | — | EP | disclosed |
| US-20030207888-A1 | Piperazine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2003-11-06 | — | — | US | disclosed |
| WO-2003064423-A1 | AZA-ARYLPIPERAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207888-A1 | Piperazine derivatives | GPR119, CPT1B, CYP2E1 | HTR2C 409/4885HTR2B 630/4885HTR2A 747/4885 |
| US-20050026925-A1 | 5HT2c receptor agonists | HTR2C, HTR2A, HTR5A | HTR2C 1/4885HTR2B 5/4885HTR2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.